SG11201901221YA - Methods for detecting aav - Google Patents

Methods for detecting aav

Info

Publication number
SG11201901221YA
SG11201901221YA SG11201901221YA SG11201901221YA SG11201901221YA SG 11201901221Y A SG11201901221Y A SG 11201901221YA SG 11201901221Y A SG11201901221Y A SG 11201901221YA SG 11201901221Y A SG11201901221Y A SG 11201901221YA SG 11201901221Y A SG11201901221Y A SG 11201901221YA
Authority
SG
Singapore
Prior art keywords
international
sanofi
rule
methods
aav
Prior art date
Application number
SG11201901221YA
Inventor
Xiaoying Jin
Catherine O'riordan
Lin Liu
Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201901221Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201901221YA publication Critical patent/SG11201901221YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111 11111111110111110100111111011100111111111111011111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/035059 Al 22 February 2018 (22.02.2018) WIP0 I PCT (51) International Patent Classification: C12N 7/00 (2006.01) G01N 33/68 (2006.01) Published: C12N 15/86 (2006.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/046814 amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 14 August 2017 (14.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/375,314 15 August 2016 (15.08.2016) US (71) Applicant: GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US). (72) Inventors: JIN, Xiaoying; c/o Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807 (US). O'RIORDAN, Catherine, R.; c/o Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807 - (US). LIU, Lin; c/o Sanofi, 55 Corporate Drive, Bridgewa- ter, NJ 08807 (US). ZHANG, Kate; c/o Sanofi, 55 Corpo- - rate Drive, Bridgewater, NJ 08807 (US). = Agent: DONAHUE, Brian, A. et al.; Morrison & Foerster = (74) LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (81) = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 ..! Declarations under Rule 4.17: ON — of inventorship (Rule 4.17(iv)) 1 1 in © en 11 in (54) Title: METHODS FOR DETECTING AAV ---- (57) : Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity GC , 1 of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of C::::) AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved N transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins. C
SG11201901221YA 2016-08-15 2017-08-14 Methods for detecting aav SG11201901221YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
PCT/US2017/046814 WO2018035059A1 (en) 2016-08-15 2017-08-14 Methods for detecting aav

Publications (1)

Publication Number Publication Date
SG11201901221YA true SG11201901221YA (en) 2019-03-28

Family

ID=59762045

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901221YA SG11201901221YA (en) 2016-08-15 2017-08-14 Methods for detecting aav
SG10201913002QA SG10201913002QA (en) 2016-08-15 2017-08-14 Methods for detecting aav

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913002QA SG10201913002QA (en) 2016-08-15 2017-08-14 Methods for detecting aav

Country Status (23)

Country Link
US (2) US11698377B2 (en)
EP (2) EP3851449A1 (en)
JP (3) JP7021191B2 (en)
KR (3) KR102538037B1 (en)
CN (1) CN110168080B (en)
AU (2) AU2017312951B2 (en)
BR (1) BR112019002934A2 (en)
CA (1) CA3033856A1 (en)
CL (2) CL2019000392A1 (en)
CR (1) CR20190127A (en)
CY (1) CY1124364T1 (en)
DK (1) DK3497207T3 (en)
ES (1) ES2863674T3 (en)
HU (1) HUE053747T2 (en)
IL (1) IL264819B1 (en)
MA (1) MA55748A (en)
MX (2) MX2019001938A (en)
PH (1) PH12019500316A1 (en)
SG (2) SG11201901221YA (en)
TN (1) TN2019000047A1 (en)
TW (2) TW202309068A (en)
WO (1) WO2018035059A1 (en)
ZA (1) ZA201900945B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
SG11201907714UA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
KR20210006327A (en) * 2018-02-27 2021-01-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Novel adeno-associated virus (AAV) vectors with reduced capsid deamidation and uses thereof
CA3091806A1 (en) * 2018-02-27 2019-09-06 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
US20210010028A1 (en) * 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US11391707B2 (en) * 2018-07-27 2022-07-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
US20210317478A1 (en) * 2018-08-21 2021-10-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
EP3870976B1 (en) * 2018-10-25 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
US20230204595A1 (en) 2020-01-03 2023-06-29 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
JP2023513004A (en) 2020-01-29 2023-03-30 ジェンザイム・コーポレーション Modified adeno-associated virus capsid proteins for ophthalmic gene therapy and methods of their use
CN111517359B (en) * 2020-04-23 2021-08-20 江南大学 Synthesis method of chiral copper sulfide super particle
RU2748540C1 (en) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Method for detecting sars-cov-2 virus by mass spectrometry
EP4295158A1 (en) * 2021-02-19 2023-12-27 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2022224965A1 (en) * 2021-04-20 2022-10-27 株式会社ユニバーサル・バイオサンプリング Specimen retention card and specimen inspection method using same
WO2023287724A1 (en) * 2021-07-12 2023-01-19 Regeneron Pharmaceuticals, Inc. Online native mass spectrometry methods for assaying viral particles
KR20240031375A (en) * 2021-07-12 2024-03-07 리제너론 파아마슈티컬스, 인크. How to Characterize Virus Particles Using Two-Dimensional Liquid Chromatography-Mass Spectrometry
CN113552349B (en) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Detection method of AAV protein coat
WO2023132338A1 (en) * 2022-01-06 2023-07-13 富士フイルム株式会社 Method and kit for identifying sugar-bound amino acid site in protein

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4827353B2 (en) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション Increased expression of single-stranded heterologous nucleotide sequences from recombinant viral vectors by designing sequences to form intrastrand base pairs
ES2256265T3 (en) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill DUVICATED PARVOVIRUS VECTORS.
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
EP1586107A2 (en) * 2002-11-22 2005-10-19 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
ES2521682T3 (en) 2003-05-21 2014-11-13 Genzyme Corporation Procedures for producing recombinant AAV virion preparations substantially free of empty capsids
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2311967B1 (en) * 2005-10-20 2017-09-20 UniQure IP B.V. Improved AAV vectors produced in insect cells
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
EP2342567A1 (en) 2008-09-19 2011-07-13 Charité Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA3077531C (en) 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2724800T3 (en) 2011-02-17 2019-09-16 Univ Pennsylvania Compositions and methods to alter tissue specificity and improve AAV9-mediated gene transfer
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
IN2014DN08812A (en) * 2012-04-18 2015-05-22 Philadelphia Children Hospital
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
US10837027B2 (en) * 2014-03-10 2020-11-17 Uniqure Ip B.V. Further improved AAV vectors produced in insect cells

Also Published As

Publication number Publication date
ES2863674T3 (en) 2021-10-11
JP2022064980A (en) 2022-04-26
AU2017312951A1 (en) 2019-04-04
KR102538037B1 (en) 2023-05-30
RU2019107207A (en) 2020-09-15
DK3497207T3 (en) 2021-03-22
CR20190127A (en) 2019-06-25
MA55748A (en) 2022-03-02
KR102425289B1 (en) 2022-07-27
JP2019533803A (en) 2019-11-21
US20210041451A1 (en) 2021-02-11
KR20220107327A (en) 2022-08-02
AU2024200349A1 (en) 2024-02-08
BR112019002934A2 (en) 2019-05-14
CL2019000392A1 (en) 2019-05-10
IL264819A (en) 2019-04-30
US20240044910A1 (en) 2024-02-08
WO2018035059A9 (en) 2019-03-14
US11698377B2 (en) 2023-07-11
EP3497207B1 (en) 2021-01-06
KR20230078834A (en) 2023-06-02
CL2019002912A1 (en) 2020-03-06
CY1124364T1 (en) 2022-07-22
MX2023009081A (en) 2023-08-08
ZA201900945B (en) 2021-06-30
JP7021191B2 (en) 2022-02-16
TW201825898A (en) 2018-07-16
JP2024023460A (en) 2024-02-21
TN2019000047A1 (en) 2020-07-15
CN110168080B (en) 2024-05-31
PH12019500316A1 (en) 2019-08-05
KR20190039253A (en) 2019-04-10
TW202309068A (en) 2023-03-01
RU2019107207A3 (en) 2021-04-29
CA3033856A1 (en) 2018-02-22
EP3497207A1 (en) 2019-06-19
TWI781953B (en) 2022-11-01
EP3851449A1 (en) 2021-07-21
HUE053747T2 (en) 2021-07-28
AU2017312951B2 (en) 2024-02-08
WO2018035059A1 (en) 2018-02-22
IL264819B1 (en) 2024-06-01
MX2019001938A (en) 2019-07-04
SG10201913002QA (en) 2020-03-30
CN110168080A (en) 2019-08-23

Similar Documents

Publication Publication Date Title
SG11201901221YA (en) Methods for detecting aav
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201909777YA (en) Modulatory polynucleotides
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201811600PA (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201811432WA (en) Rna for cancer therapy
SG11201809684YA (en) Adeno-associated virus variant capsids and methods of use thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201808196UA (en) Neoantigens and methods of their use
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900910TA (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
SG11201908391XA (en) Methods for modulating an immune response
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201906213UA (en) Modulating expression of polypeptides via new gene switch expression systems
SG11201808751SA (en) T cell receptors
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11202000145XA (en) Methods and systems for conditionally regulating gene expression
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport